Fresenius Medical Care (NYSE:FMS) Price Target Raised to $30.00

Fresenius Medical Care (NYSE:FMS) had its price objective raised by Truist Financial from $25.00 to $30.00 in a research note issued to investors on Monday,Benzinga reports. They currently have a hold rating on the stock.

Separately, StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th.

Fresenius Medical Care Price Performance

Shares of FMS stock opened at $28.09 on Monday. Fresenius Medical Care has a fifty-two week low of $17.93 and a fifty-two week high of $28.59. The firm has a market capitalization of $16.48 billion, a price-to-earnings ratio of 23.21, a PEG ratio of 0.76 and a beta of 0.85. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The stock’s 50-day simple moving average is $24.64 and its 200-day simple moving average is $23.50.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.01. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. The business had revenue of $5.54 billion for the quarter, compared to analyst estimates of $4.71 billion. As a group, equities analysts forecast that Fresenius Medical Care will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The company also recently announced an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be given a $0.7871 dividend. The ex-dividend date of this dividend is Friday, May 23rd. This represents a yield of 1.9%. This is a positive change from Fresenius Medical Care’s previous annual dividend of $0.44. Fresenius Medical Care’s dividend payout ratio is currently 49.11%.

Institutional Investors Weigh In On Fresenius Medical Care

Large investors have recently bought and sold shares of the company. Callan Family Office LLC purchased a new stake in Fresenius Medical Care in the fourth quarter valued at approximately $502,000. Raymond James Financial Inc. acquired a new position in Fresenius Medical Care in the fourth quarter valued at approximately $405,000. Callan Capital LLC acquired a new position in Fresenius Medical Care in the fourth quarter valued at approximately $297,000. Sanctuary Advisors LLC acquired a new position in Fresenius Medical Care in the fourth quarter valued at approximately $983,000. Finally, ABC Arbitrage SA acquired a new position in Fresenius Medical Care in the fourth quarter valued at approximately $4,215,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.